The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands.

Micha J PilzSimon SeyringerLára R HallssonAndrew BottomleyFemke JansenMadeleine T KingRichard NormanMarianne J RuttenIrma M Verdonck-de LeeuwPeter D SiersemaEva Maria Gamper

Published in: The European journal of health economics : HEPAC : health economics in prevention and care (2024)

The Dutch EORTC QLU-C10D showed good comparative validity in patients undergoing treatment. Our results underline the benefit that can be achieved by using a cancer-specific PBM for generating health utilities for cancer patients from a measurement perspective.

Keyphrases

papillary thyroid
patients undergoing
healthcare
public health
squamous cell
mental health
health information
lymph node metastasis
risk assessment
replacement therapy
smoking cessation